Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Cytosorbents Corp | v352915_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 14, 2013
CYTOSORBENTS CORPORATION
(Exact name of registrant as specified in its charter)
| Nevada | 000-51038 | 98-0373793 |
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
7 Deer Park Drive, Suite K
Monmouth Junction, New Jersey 08852
(Address of principal executive offices)(Zip Code)
Registrant's telephone number, including area code: (732) 329-8885
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01 | Other Events. |
On August 14, 2013, CytoSorbents Corporation (the "Company") issued a press release announcing its financial results for the period ended June 30, 2013. A copy of the release is furnished herewith as Exhibit 99.1.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
| Exhibit No. | Description |
| 99.1 | Press Release, dated August 14, 2013, relating to CytoSorbents Corporation's financial results for the period ended June 30, 2013 (filed herewith). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CYTOSORBENTS CORPORATION | |||
| Date: August 14, 2013 | By: | /s/ Dr. Phillip P. Chan | |
|
Dr. Phillip P. Chan President and CEO |
|||